Related Experiment Video
Updated: Apr 6, 2026

Whole Body Vibration Methods with Survivors of Polio
Published on: October 17, 2018
The Effect of Oral Polio Vaccine at Birth on Infant Mortality: A Randomized Trial
Najaaraq Lund1, Andreas Andersen2, Anna Sofie K Hansen3
1Research Center for Vitamins and Vaccines, Statens Serum Institut, Copenhagen Department of Pediatrics, Kolding Hospital/University of Southern Denmark, Kolding.
Insights
Oral polio vaccine at birth (OPV0) may offer nonspecific protection against infant mortality, particularly when administered early. This randomized trial found no increased mortality, suggesting a potential protective effect against infectious diseases.
Area of Science:
- Immunology
- Pediatrics
- Public Health
Background:
- Observational studies suggested routine vaccines, including oral polio vaccine at birth (OPV0), might have nonspecific effects on mortality, with some indicating increased male infant mortality.
- The potential for non-specific effects of vaccines on mortality necessitates rigorous investigation through randomized controlled trials.
Purpose of the Study:
- To investigate the effect of oral polio vaccine given at birth (OPV0) on infant mortality in a randomized trial setting.
- To determine if OPV0 is associated with increased or decreased mortality in infants, contradicting previous observational findings.
Main Methods:
- A randomized trial involving 7012 healthy neonates assigned to BCG vaccination only or BCG with OPV0.
- All infants received subsequent oral polio vaccine (OPV) doses and pentavalent vaccines at 6, 10, and 14 weeks.
- Mortality was tracked to 12 months of age using Cox regression to calculate hazard ratios (HRs).
Main Results:
- The trial contradicted the hypothesis of increased mortality with OPV0; the overall HR for BCG + OPV0 vs. BCG only was 0.83 (95% CI, 0.61-1.13).
- A significant protective effect was observed for infants receiving BCG + OPV0 within the first 2 days of life (HR 0.58, 95% CI, 0.38-0.90).
- Beneficial effects were noted particularly in males when OPV0 was administered early, with an HR of 0.55 (95% CI, 0.32-0.95) from enrollment until OPV campaigns.
Conclusions:
- This randomized trial suggests OPV0 may be associated with nonspecific protection against infectious disease mortality, especially when given early.
- The findings highlight the need for continued mortality monitoring during vaccine transitions, such as the phasing out of OPV.
- This study provides crucial evidence from the only randomized trial on the mortality effects of OPV0.
Background:
Routine vaccines may have nonspecific effects on mortality. An observational study found that OPV given at birth (OPV0) was associated with increased male infant mortality. We investigated the effect of OPV0 on infant mortality in a randomized trial in Guinea-Bissau.
Methods:
A total of 7012 healthy normal-birth-weight neonates were randomized to BCG only (intervention group) or OPV0 with BCG (usual practice). All children were to receive OPV with pentavalent vaccine (diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and hepatitis B) at 6, 10, and 14 weeks of age. Seven national OPV campaigns were also conducted during the trial period. Children were followed to age 12 months. We used Cox regression to calculate hazard ratios (HRs) for mortality.
Results:
The trial contradicted the original hypothesis about OPV0 increasing male infant mortality. Within 12 months, 73 children in the BCG + OPV group and 87 children in the BCG-only group died, all from infectious diseases. Comparing BCG + OPV0 vs BCG only, the HR was 0.83 (95% confidence interval [CI], .61-1.13): 0.72 (95% CI, .47-1.10) in boys and 0.97 (95% CI, .61-1.54) in girls. For children enrolled within the first 2 days of life, the HR for BCG + OPV0 vs BCG only was 0.58 (95% CI, .38-.90). From enrollment until the time of OPV campaigns, the HR was 0.68 (95% CI, .45-1.00), the beneficial effect being separately significant for males (0.55 [95% CI, .32-.95]).
Conclusions:
This is the only randomized trial of the effect of OPV0 on mortality. OPV0 may be associated with nonspecific protection against infectious disease mortality, particularly when given early in life. There are reasons to monitor mortality when OPV is being phased out.
Clinical Trials Registration:
NCT00710983.
Related Concept Videos
Development of the Oral Microbiota
Vaccinations
Bias in Epidemiological Studies
Drug Dosing: Infants and Children
Confounding in Epidemiological Studies
What is an Experiment?

